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Background:  There is now guidance for interpreting troponin (cTn) results applicable to high sensitive (hs) assays for diagnosing myocardial 
infarction (MI). For chest pain patients (pts) without ECG findings of ischemia we determined the additional proportion of pts diagnosed with MI and 
their prognosis with an hsTnI versus a contemporary cTnI assay.
Methods:  From 8 emergency departments (ED), 663 patients were evaluated with cTnI and hsTnI (Siemens Centaur® TnI-Ultra® [99th% 40 pg/
mL, 10% coefficient of variation (CV) at 30 pg/mL] and a research hs assay on the Vista® 1500 [99th% 9 pg/mL, 10%CV at 3 pg/mL) at two times 
(presentation and 8±4 hours). MI was defined as one value > the 99th% and a change > 3 X the CV of the initial value. For hsTnI, change also had to 
be > 3 pg/mL to account for biologic variation. Echocardiograms were done within 96 hours. The 6 month outcome included the composite of death, 
MI and revascularization as well as ED observation or readmission for chest pain.
Results:  The baseline characteristics and outcomes of pts without MI, MI by cTnI and additional MIs by hsTnI are shown in the Table. Fourteen 
pts were excluded with cTnI>40 pg/mL, but not meeting the MI definition. Pts identified by hsTnI with MI have similar characteristics and outcomes 
compared to patients with MI by the cTnI assay.
Conclusions:  Utilizing an hsTnI assay among chest pain pts without ECG evidence of ischemia identified 51% more patients with MI than a 
contemporary cTnI assay. These patients may benefit from similar MI management. 
